Atlas Trials

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Clinical trial NCT06328036 · WITHDRAWN

Trial details

NCT number
NCT06328036
Sponsor
National Cancer Institute (NCI)
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma, IDH-Wildtype
Start date
2025-04-30
Primary completion
2025-07-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.